Global Vaccine Delivery Devices Market - 2022-2029

Market Overview

Vaccine Delivery Devices Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.2% during the forecast period (2022-2029).

The vaccine delivery device is used for proper vaccine delivery to ensure successful vaccination. Mainly, most vaccines are administered via the subcutaneous (SC) or intramuscular (IM) routes.

Market Dynamics

The vaccine delivery devices market growth is driven by the rise in the prevalence of different infectious diseases, such as COVID-19, an increase in the geriatric population, and research and development activities.

The rising awareness of immunizations in public is expected to drive the market growth

The increasing prevalence of diseases, such as COVID-19, is expected to boost the market over the forecast period. National Immunization Awareness Month (NIAM) is celebrated in August month. As per NIAM 2021 data, COVID-19 cases are increasing nationwide, so it is necessary to take the vaccination. NIAM encourages National Immunization Awareness and discusses strategies for increasing immunizations for COVID and other diseases such as diphtheria, measles, mumps, polio, rubella, and tetanus, among others diseases. The strategies include local outreach to underreserved communities to reduce vaccine hesitancy, encouraging annual checkups of pediatric patients, and advocating to keep up the immunization schedule.

In addition, the key players are adopting the market strategies such as acquisition and product development. For instance, in April 2020, Zealand Pharma acquired Valeritas Holdings, a U.S.-based medical company, for USD 23 Mn. Also, in November 2021, Gerresheimar partnered with Midas Pharma for a new auto-injector. The partnership contains the development and marketing of a new-generation auto-injector.

Furthermore, in August 2021, the Vaccine developer Serum Institute of India acquired a 50% stake in pharma packaging company Schott Kaisha for an amount that was not disclosed. Schott AG is a Germany-based player that manufactures vials, syringes, and cartridges.

The shortage of vaccine delivery devices will hamper the growth of the market

However, many people cannot afford healthcare due to advanced treatment for several diseases. For instance, the cost of Spinraza, marketed by Biogen and used for the treatment of spinal muscular atrophy, is around US$ 750,000 per patient in the first year and US$ 375,000 annually. These factors negatively affecting on market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global vaccine delivery devices market.

According to November 2021 PATH data report, the expected spike in demand for syringes for COVID-19 vaccines, anticipated to total more than 4 billion from the year-end of 2021 to mid-2022, is due to the estimated increase in COVID-19 vaccine dose deliveries to countries coming through vaccine COVAX, large donations from governments, and bilateral deals. The PATH modeling estimates a global gap of 1.2 billion AD syringes based on global supply and demand data. For instance, in November 2021, New PATH modeling anticipates a global market supply gap of 1.2 billion auto-disable syringe safe-injection devices for COVID-19 vaccine delivery. This gap risks becoming a stoppage that could risk the timely delivery of vaccines in countries worldwide.

On the other hand, challenges to syringe supply, such as export restrictions, shipping delays, new manufacturing lines failing to receive World Health Organization guidelines, or delays in completing planned manufacturing expansions, could broaden the cumulative gap to more than 2 billion during this period. Also, Booster doses could create further demand pressures on the market.

Segment Analysis

The microneedles segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The microneedles segment is expected to boost the market throughout the forecast. As per the article published in Pharmaceutics 2022, the maintenance of the vaccine potency, transportation, and needle waste generation have become major issues. Moreover, needle phobia and vaccine hesitancy are hurdles to successful mass vaccination. Dissolvable microneedles for vaccination could act as a major paradigm shift in attaining the desired goal of vaccinating billions in the shortest time possible.

Using dissolvable microneedle patches would improve the dosing accuracy, ensuring the precise delivery of the vaccines. Using biodegradable microneedles for transdermal immunization is a fast-developing topic of study and application. Microneedles have several benefits over traditional immunization, such as intramuscular and subcutaneous injections, aside from the fact that they are painless, slowing the release of vaccination antigens. Vaccine components in microneedles may be in solution or suspension, coated in nano or microparticles, or based on nucleic acids. Due to the combined advantages of particulate vaccinations and pain-free vaccination, the use of microneedles to administer particle-based immunizations is growing rapidly.

In addition, in May 2020, Altaris Capital Partners acquired Kindeva Drug Delivery for $650 million. With the help of the expertise of 3M and the Kindeva team, Altaris able to develop innovative drug delivery technologies in the healthcare sector.

Geographical Analysis

North America region holds the largest market share of the global vaccine delivery devices market

North America dominates the market for vaccine delivery devices and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure, rising chronic and infectious diseases, and launching new products. The presence of market players and government initiatives for public health drives the market. For instance, the United States government has ordered 286 million needles and syringes from B.D., with 256 million to be given by January 2021. These devices will help to deliver a safe, effective COVID-19 vaccine to millions of Americans as soon as one is available. In July 2020, ASPR's Biomedical Advanced Research and Development Authority (BARDA) invested approximately $42 million into a $70 million capital project to further expand B.D.'s operations and manufacturing lines in Holdrege, Neb. The expansion builds on the company's deep commitment and legacy in supporting U.S. vaccination efforts through the domestic manufacturing of needles and syringes.

Competitive Landscape

The vaccine delivery devices market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are 3M, Becton Dickinson & Company, Inovio Pharmaceutical Inc., PharmaJet, Vaxxas, Gerresheimer AG, SCHOTT AG, Corium International, Inc. and Intravaac, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global vaccine delivery devices market.

For instance,

• In 2021, Rockwell industries launched the world's hybrid freezer, which is used to store the COVID-19 vaccine.
• In 2021, Becton and Dickison launched a needles & syringes multi-drug delivery facility device that helps administer COVID-19 vaccines.

Becton Dickinson & Company

Overview:

Becton Dickinson & Company is an American multinational medical technology company headquartered in the United States that provides advancing health solutions for patient safety and clinical outcomes. It offers the vaccine syringe and other drug delivery systems in the market.

Product Portfolio:

BD Hypak: It is used for vaccines glass pre-fillable syringe system, a reliable glass pre-fillable syringe system specifically optimized for vaccinations. The system fulfills customer needs for better processability of the syringe during filling and packaging operations.

The global vaccine delivery devices market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.